The University of Chicago Header Logo

Connection

Russell Cohen to Crohn Disease

Back to Details
This is a "connection" page, showing publications Russell Cohen has written about Crohn Disease.
Russell Cohen
Connection Strength
7.025
Crohn Disease
  1. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis. 2020 Feb 10; 14(2):192-204.
    View in: PubMed
    Score: 0.393
  2. Maneuvering Clinical Pathways for Crohn's Disease. Curr Gastroenterol Rep. 2019 Apr 23; 21(5):20.
    View in: PubMed
    Score: 0.372
  3. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.302
  4. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.271
  5. Dietary fiber intake and Crohn's disease. Gastroenterology. 2014 Apr; 146(4):1133.
    View in: PubMed
    Score: 0.260
  6. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.213
  7. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis. 2008 Dec; 14(12):1707-14.
    View in: PubMed
    Score: 0.181
  8. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008 Jun; 14(6):738-43.
    View in: PubMed
    Score: 0.175
  9. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007 Nov; 62(11):1013-4.
    View in: PubMed
    Score: 0.168
  10. Postoperative management of ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005 Dec; 7(6):492-9.
    View in: PubMed
    Score: 0.147
  11. Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):763-771.
    View in: PubMed
    Score: 0.144
  12. Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2025 Sep; 23(10):1817-1823.
    View in: PubMed
    Score: 0.136
  13. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004; 64(16):1767-77.
    View in: PubMed
    Score: 0.129
  14. Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
    View in: PubMed
    Score: 0.128
  15. Infliximab at 5 years--tweaking the recipe for success? Gastroenterology. 2003 Dec; 125(6):1902-3.
    View in: PubMed
    Score: 0.128
  16. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
    View in: PubMed
    Score: 0.122
  17. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002 Sep; 16(9):1603-9.
    View in: PubMed
    Score: 0.117
  18. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002 Aug; 35(2):151-6.
    View in: PubMed
    Score: 0.117
  19. Endoscopy of the small bowel in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002 Jul; 12(3):485-93.
    View in: PubMed
    Score: 0.116
  20. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 07; 163(1):204-221.
    View in: PubMed
    Score: 0.114
  21. Crohn's disease and Takayasu's arteritis. J Clin Gastroenterol. 2002 Apr; 34(4):454-6.
    View in: PubMed
    Score: 0.114
  22. Cost utility of initial medical management for Crohn's disease perianal fistula. Gastroenterology. 2002 Apr; 122(4):1187-8; author reply 1188-90.
    View in: PubMed
    Score: 0.114
  23. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
    View in: PubMed
    Score: 0.114
  24. Infliximab as first-line therapy for severe Crohn's disease? Inflamm Bowel Dis. 2002 Jan; 8(1):58-9; discussion 63-5.
    View in: PubMed
    Score: 0.112
  25. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
    View in: PubMed
    Score: 0.108
  26. Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
    View in: PubMed
    Score: 0.107
  27. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22.
    View in: PubMed
    Score: 0.107
  28. The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
    View in: PubMed
    Score: 0.105
  29. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
    View in: PubMed
    Score: 0.105
  30. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44.
    View in: PubMed
    Score: 0.105
  31. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
    View in: PubMed
    Score: 0.104
  32. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.
    View in: PubMed
    Score: 0.104
  33. Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Aliment Pharmacol Ther. 2020 08; 52(3):559-560.
    View in: PubMed
    Score: 0.102
  34. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
    View in: PubMed
    Score: 0.099
  35. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000 Feb; 95(2):524-30.
    View in: PubMed
    Score: 0.098
  36. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.096
  37. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.092
  38. Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-a4ß7 and anti-PD1 antibodies. J Immunother Cancer. 2019 01 06; 7(1):1.
    View in: PubMed
    Score: 0.091
  39. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.089
  40. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688.
    View in: PubMed
    Score: 0.088
  41. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.088
  42. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.086
  43. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.086
  44. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501.
    View in: PubMed
    Score: 0.086
  45. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.085
  46. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.075
  47. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.071
  48. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23.
    View in: PubMed
    Score: 0.064
  49. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.064
  50. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.061
  51. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22.
    View in: PubMed
    Score: 0.058
  52. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.056
  53. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009 Aug; 43(7):613-6.
    View in: PubMed
    Score: 0.047
  54. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
    View in: PubMed
    Score: 0.038
  55. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30.
    View in: PubMed
    Score: 0.038
  56. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8.
    View in: PubMed
    Score: 0.035
  57. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
    View in: PubMed
    Score: 0.034
  58. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
    View in: PubMed
    Score: 0.034
  59. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.025
  60. The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. Semin Gastrointest Dis. 2000 Jan; 11(1):10-7.
    View in: PubMed
    Score: 0.024
  61. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
    View in: PubMed
    Score: 0.024
  62. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.024
  63. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28.
    View in: PubMed
    Score: 0.022
  64. Ulcerative Colitis Care Pathway. Gastroenterology. 2015 Jul; 149(1):238-45.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.